Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis

Jemal, 2006, Cancer statistics, 2006, CA Cancer J Clin, 56, 106, 10.3322/canjclin.56.2.106 American Cancer Society, 2005 Quiet, 1995, Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up, J Clin Oncol, 13, 1144, 10.1200/JCO.1995.13.5.1144 Rosen, 1991, Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study, J Clin Oncol, 9, 1650, 10.1200/JCO.1991.9.9.1650 Rosen, 1989, Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years, J Clin Oncol, 7, 1239, 10.1200/JCO.1989.7.9.1239 Early Breast Cancer Trialists’ Collaborative Group, 1998, Tamoxifen for early breast cancer: an overview of the randomised trials, Lancet, 351, 1451, 10.1016/S0140-6736(97)11423-4 Cummings, 1998, Endogenous hormones and the risk of hip and vertebral fractures among older women, N Engl J Med, 339, 733, 10.1056/NEJM199809103391104 Heshmati, 2002, Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women, J Bone Miner Res, 17, 172, 10.1359/jbmr.2002.17.1.172 Hadji P. Aromatase inhibitor-associated bone loss in breast cancer. Touch Brief: Eur Oncol Dis 2007:35–8. <http://www.touchbriefings.com/pdf/2789/Hadji.pdf>. Coates, 2007, Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98, J Clin Oncol, 25, 486, 10.1200/JCO.2006.08.8617 Coombes, 2007, Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial, Lancet, 369, 559, 10.1016/S0140-6736(07)60200-1 Goss, 2005, Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17, J Natl Cancer Inst, 97, 1262, 10.1093/jnci/dji250 Howell, 2005, Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer, Lancet, 365, 60, 10.1016/S0140-6736(04)17666-6 Jakesz, 2005, Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial, Lancet, 366, 455, 10.1016/S0140-6736(05)67059-6 Geisler, 2002, Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study, J Clin Oncol, 20, 751, 10.1200/JCO.2002.20.3.751 Geisler, 1998, In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients, Clin Cancer Res, 4, 2089 Coleman, 2007, Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study, Lancet Oncol, 8, 119, 10.1016/S1470-2045(07)70003-7 Eastell, 2008, Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230, J Clin Oncol, 26, 1051, 10.1200/JCO.2007.11.0726 Perez, 2006, Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17, J Clin Oncol, 24, 3629, 10.1200/JCO.2005.05.4882 Saarto, 2001, The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer, Br J Cancer, 84, 1047, 10.1054/bjoc.2001.1729 Kanis, 1999, A high incidence of vertebral fracture in women with breast cancer, Br J Cancer, 79, 1179, 10.1038/sj.bjc.6690188 Chen, 2005, Fracture risk among breast cancer survivors. Results from the Women's Health Initiative Observational Study, Arch Int Med, 165, 552, 10.1001/archinte.165.5.552 Dowsett, 1995, In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer, Clin Cancer Res, 1, 1511 Geisler, 1996, Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer, Br J Cancer, 74, 1286, 10.1038/bjc.1996.531 Brufsky, 2007, Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer, J Clin Oncol, 25, 829, 10.1200/JCO.2005.05.3744 Coleman, 2006, Effect of anastrozole on bone mineral density: 5-year results from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial, J Clin Oncol, 24, 5s Eastell, 2006, Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230), J Bone Miner Res, 21, 1215, 10.1359/jbmr.060508 Gnant, 2007, Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group, J Clin Oncol, 25, 820, 10.1200/JCO.2005.02.7102 Lonning, 2005, Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer, J Clin Oncol, 23, 5126, 10.1200/JCO.2005.07.097 Reid, 2002, Intravenous zoledronic acid in postmenopausal women with low bone mineral density, N Engl J Med, 346, 653, 10.1056/NEJMoa011807 Warming, 2002, Changes in bone mineral density with age in men and women: a longitudinal study, Osteoporos Int, 13, 105, 10.1007/s001980200001 Lindsey, 1997, Consensus development statement: who are candidates for prevention and treatment for osteoporosis?, Osteoporos Int, 7, 1, 10.1007/BF01623453 Bonjour, 1994, Peak bone mass, Osteoporos Int, 4, 7, 10.1007/BF01623429 Christiansen, 1994, Postmenopausal bone loss and the risk of osteoporosis, Osteoporos Int, 4, 47, 10.1007/BF01623436 World Health Organization, 2003 Riggs, 2002, Sex steroids and the construction and conservation of the adult skeleton, Endocr Rev, 23, 279, 10.1210/edrv.23.3.0465 Purohit, 2002, Regulation of estrogen synthesis in postmenopausal women, Steroids, 67, 979, 10.1016/S0039-128X(02)00046-6 Forbes, 2008, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial, Lancet Oncol, 9, 45, 10.1016/S1470-2045(07)70385-6 Kanis, 2001, Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds, Osteoporos Int, 12, 989, 10.1007/s001980170006 Kanis, 2004, A meta-analysis of prior corticosteroid use and fracture risk, J Bone Miner Res, 19, 893, 10.1359/JBMR.040134 van Der Voort, 2003, Early menopause: increased fracture risk at older age, Osteoporos Int, 14, 525, 10.1007/s00198-003-1408-1 De Vries, 2007, Fracture risk with intermittent high-dose oral glucocorticoid therapy, Arthritis Rheum, 56, 208, 10.1002/art.22294 Kanis, 1994, The diagnosis of osteoporosis, J Bone Miner Res, 9, 1137, 10.1002/jbmr.5650090802 National Osteoporosis Foundation. NOF physician's guide: pharmacologic options. <www.nof.org/physguide/phamacologic.htm> [accessed 03.08.2007]. Siris, 2004, Bone mineral density thresholds for pharmacological intervention to prevent fractures, Arch Int Med, 164, 1108, 10.1001/archinte.164.10.1108 Hillner, 2003, American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer, J Clin Oncol, 21, 4042, 10.1200/JCO.2003.08.017 Thurlimann, 2005, A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer, N Engl J Med, 353, 2747, 10.1056/NEJMoa052258 Lester, 2008, Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: two-year results from the ARIBON study, J Clin Oncol, 26, 19s Van Poznak C, Hannon R.A, Clack G. et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis. In: Presented at the San Antonio Breast Cancer symposium. December 13–15 2007, San Antonio, Texas [abstract 502]. Siris, 2006, Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases, Mayo Clin Proc, 81, 1013, 10.4065/81.8.1013 Aapro, 2006, Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program, Breast, 15, S30, 10.1016/j.breast.2006.01.005 Brufsky, 2006, Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update, Semin Oncol, 33, S13, 10.1053/j.seminoncol.2006.03.022 Bundred N, Campbell I, Coleman R, et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZOFAST study). In: Presented at the 5th European breast cancer conference. 21-25 March 2006. Nice, France [abstract 12]. Schenk N, Lombart A, Frassoladti A, et al. The E-ZO-FAST trial: zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvantletrozole. In: Presented at the 14th European cancer conference (ECCO); 23-27 September 2007. Barcelona, Spain, [abstract 2008]. Brufsky, 2006, Twenty-four month follow-up of zoledronic acid (ZA) on aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET), Breast Cancer Res Treat, 100, S233 Brufsky, 2008, Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole, Oncologist, 13, 503, 10.1634/theoncologist.2007-0206 Gnant, 2007, Breast Cancer Res Treat, 106, S8 Seeman, 2006, Bone quality—the material and structural basis of bone strength and fragility, N Engl J Med, 354, 2250, 10.1056/NEJMra053077 Gnant, 2008, Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12, J Clin Oncol, 26, 1006s Black, 2007, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis, N Engl J Med, 356, 1809, 10.1056/NEJMoa067312 Chapurlat, 2006, Drug insight: bisphosphonates for postmenopausal osteoporosis, Nat Clin Pract Endocrinol Metab, 2, 211, 10.1038/ncpendmet0121 Siris, 2004, Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50–64 and 65 and older: results from the National Osteoporosis Risk Assessment (NORA), J Bone Miner Res, 19, 1215, 10.1359/JBMR.040508 Brufsky, 2006, An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving letrozole (LET), Breast Cancer Res Treat, 100, S25 Llombart A. Zoledronic acid in the prevention of aromatase inhibitor-associated bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (E-ZO-FAST trial). In: Presented at the 14th European cancer conference (ECCO). 23–27 September 2007, Barcelona, Spain [abstract 2044]. Adachi, 2002, The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women, BMC Musculoskelet Disord, 3, 11, 10.1186/1471-2474-3-11 De Laet, 1997, Bone density and risk of hip fracture in men and women: cross sectional analysis, BMJ, 315, 221, 10.1136/bmj.315.7102.221 Logman F, Heeg B., Botteman M., Marfatia A.A., van Hout B.A. Cost-effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitor: application to the United Kingdom. Presented at the 14th European cancer conference (ECCO). 23–27 September 2007, Barcelona, Spain [abstract 1146]. Whannel, 2006, The need for DXA assessment of breast cancer patients following 5 years tamoxifen prior to starting an aromatase inhibitor, Breast Cancer Res Treat, 100, S187 Hadji, 2008, Practical guidance for the management of aromatase inhibitor-associated bone loss, Ann Oncol, 10.1093/annonc/mdn164